GlaxoSmithKline Pharma Q4 net profit grows 46% to Rs 194.5 crore, declares Rs 32/share dividend

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK plc, a global biopharma company, has a legacy in India of nearly 100 years.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Drug major GlaxoSmithKline Pharmaceuticals Ltd on May 17 reported a 46 percent rise in net profit at Rs 194.5 crore for the January-March quarter of FY24 from Rs 133 crore a year ago.

Revenue from operations inched up 18 percent up to Rs 930 crore from Rs 787 crore last fiscal, the company said in a regulatory filing.

At the operating level, EBITDA rose to Rs 258 crore in the third quarter of this fiscal over Rs 169 crore YoY. EBITDA margins came in at 27.7 percent against 21.5 percent (YoY).

The company also reported a one-time gain at Rs 2.4 crore against Rs 10.4 crore forma year ago.

The Board of Directors recommend a dividend of Rs. 32 per equity share of face value of Rs.10 each.

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of the UK-based GSK Plc, a global biopharma company, has a legacy in India of nearly 100 years.